Display options
Cite
Cheraghi H, Khaki Z, Malekinejad H, et al. Fructooligosaccharide raftilose reduces the mycophenolate mofetil-induced complications: Hematological and biochemical alterations. Vet Res Forum. 2015;6(4):319-26
Cheraghi, H., Khaki, Z., Malekinejad, H., & Sasani, F. (2015). Fructooligosaccharide raftilose reduces the mycophenolate mofetil-induced complications: Hematological and biochemical alterations. Veterinary research forum : an international quarterly journal, 6(4), 319-26.
Cheraghi, Hadi, et al. "Fructooligosaccharide raftilose reduces the mycophenolate mofetil-induced complications: Hematological and biochemical alterations." Veterinary research forum : an international quarterly journal vol. 6,4 (2015): 319-26.
Cheraghi H, Khaki Z, Malekinejad H, Sasani F. Fructooligosaccharide raftilose reduces the mycophenolate mofetil-induced complications: Hematological and biochemical alterations. Vet Res Forum. 2015;6(4):319-26. Epub 2015 Dec 15. PMID: 26973768; PMCID: PMC4769338.
Copy Download .nbib Format: NLM
Share it on

Vet Res Forum. 2015;6(4):319-26. Epub 2015 Dec 15.

Fructooligosaccharide raftilose reduces the mycophenolate mofetil-induced complications: Hematological and biochemical alterations.

Veterinary research forum : an international quarterly journal

Hadi Cheraghi, Zohreh Khaki, Hassan Malekinejad, Farhang Sasani

Affiliations

  1. Department of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran;
  2. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran;; Department of Basic Sciences, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran;
  3. Department of Veterinary Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.

PMID: 26973768 PMCID: PMC4769338

Abstract

Mycophenolate mofetil (MMF) is a selective inhibitor of Inosine-5'-monophosphate dehydrogenase. Gastrointestinal (GI) disturbances in immature ones are reported for MMF-induced compilations, which in the case of occurrence dose reduction is required. Thus, in the present study, the fructooligosaccharide raftilose(®) (RFT) was co-administrated with MMF to estimate the protective effect of RFT against MMF-induced GI complications. Thirty six immature male Wistar rats were divided into six groups including: Control (normal saline), RFT-treated (100 mg kg(-1)), MMF-treated (20 mg kg(-1)), MMF + LRFT (50 mg kg(-1)), MMF + MRFT (100 mg kg(-1)) and MMF + HRFT (200 mg kg(-1)) groups. The hematocrit (Hct), lymphocyte/total WBC, feces water content and pH were analyzed. Moreover, the hepatic functional tests, kidney-related biomarkers, lipid and protein profiles, total antioxidant capacity (TAC), malondialdehyde (MDA) and nitric oxide (NO) contents were assessed. Co-administration of RFT stabilized the MMF-reduced body weight. The MMF significantly diminished Hct and lymph/total WBC (p < 0.05). Only MRFT enhanced the lymphocyte/total WBC. Increased water content, no changes in feces pH, increased serum ALT and AST, no alteration in urea and mild enhancement in creatinine were demonstrated in MMF-received animals. However, RFT at low dose ameliorated the feces parameters and reduced ALT. No significant changes were demonstrated for serum lipid and protein profiles in MMF- and RFT + MMF-treated groups. The RFT enhanced the serum TAC, reduced MDA and NO contents. In conclusion, our data suggested that RFT could be considered as an effective agent to subsidize the MMF-induced clinical, hematological and biochemical disorders.

Keywords: Fructooligosaccharide; Hematology; Mycophenolate mofetil; Oxidative stress

References

  1. Case Rep Pediatr. 2012;2012:624168 - PubMed
  2. Immunopharmacology. 2000 May;47(2-3):85-118 - PubMed
  3. Diabetes Care. 2010 Nov;33(11):2416-23 - PubMed
  4. Transplant Proc. 2011 Sep;43(7):2741-6 - PubMed
  5. Transpl Int. 2004 Sep;17 (8):463-7 - PubMed
  6. Cell Immunol. 1999 Nov 1;197(2):136-44 - PubMed
  7. Lupus. 2005;14 Suppl 1:s2-8 - PubMed
  8. Transplantation. 2005 Oct 15;80(2 Suppl):S181-90 - PubMed
  9. Vet Res Forum. 2013 Spring;4(2):77-83 - PubMed
  10. J Perinatol. 2007 Jan;27(1):62-4 - PubMed
  11. Transplantation. 2006 Jul 15;82(1):102-7 - PubMed
  12. J Heart Lung Transplant. 2002 Oct;21(10 ):1074-9 - PubMed
  13. Am J Physiol Renal Physiol. 2007 Aug;293(2):F616-23 - PubMed
  14. J Agric Food Chem. 2012 Dec 5;60(48):11942-51 - PubMed
  15. Eur Neurol. 2001;46(1):53-4 - PubMed
  16. Br J Nutr. 2002 May;87 Suppl 2:S145-51 - PubMed
  17. Clin Transplant. 2005 Dec;19(6):779-84 - PubMed
  18. Chem Res Toxicol. 1998 Oct;11(10 ):1176-83 - PubMed
  19. Mol Nutr Food Res. 2013 Aug;57(8):1468-72 - PubMed
  20. J Am Soc Nephrol. 2002 Mar;13(3):759-68 - PubMed
  21. Anal Biochem. 1977 Dec;83(2):346-56 - PubMed
  22. Biol Pharm Bull. 2012;35(7):1009-13 - PubMed
  23. Clin Transplant. 2000 Dec;14(6):586-91 - PubMed
  24. Diabetes. 2011 Nov;60(11):2775-86 - PubMed
  25. Clin Nutr. 2010 Dec;29(6):832-9 - PubMed
  26. Anal Biochem. 1996 Jul 15;239(1):70-6 - PubMed
  27. Arch Latinoam Nutr. 2009 Dec;59(4):358-68 - PubMed
  28. Transpl Immunol. 2009 Dec;22(1-2):12-7 - PubMed
  29. Gut. 2003 Jun;52(6):827-33 - PubMed
  30. J Nutr. 2011 May;141(5):971-7 - PubMed
  31. Tidsskr Nor Laegeforen. 2005 Jun 16;125(12 ):1650-2 - PubMed
  32. Adv Pediatr. 2005;52:77-113 - PubMed

Publication Types